clinical trial · NCT06405633
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Alpha-1 Antitrypsin DeficiencyWVE-006
brief summary
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
started
Jul 19, 2024
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Apr 14, 2026
official title
A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol